A leader in the restoration and regeneration of tissue function, Videregen is a clinical stage company with a primary focus on treating airway diseases and thymus dysfunction. Thymus dysfunction is implicated in a number of immune disorders and age-related diseases. Videregen utilises its proprietary tissue and cell processing technologies, to develop high quality standardised tissue restoration products, which it will bring to market in countries across the world. These technologies have great potential for use across multiple disease areas and will be leveraged to develop a broad portfolio of products in areas of unmet medical need. Privately funded, the company is collaborating with centres of excellence across the UK and Europe to drive product development. Collectively, Videregen’s successful management team has over 100 years’ experience in both development and commercialisation of tissue restoration products, at companies such as Tissue Science Laboratories (now part of Covidien/Medtronic), Tissue Regenix and Johnson & Johnson Medical/Ethicon. Videregen has office and laboratory facilities in Leeds, while its head office is based in Liverpool, UK.